The goal of our U.S. and European business development efforts is to identify and acquire /license post-proof of concept clinical opportunities and/or already commercialized pharmaceutical products that treat serious diseases afflicting a limited and identifiable patient population with limited or no treatment options.

Our intent is to support these products with a targeted marketing effort serving physician specialists and patients. Through this type of commercialization we can provide a high level of service, attain better product margins, and maintain control of the distribution of our product(s).

Our strategy is to target serious diseases by building franchises within narrowly focused prescribing groups with patients as our primary focus. By focusing on patients and physicians we believe can better serve the medical community and create significant growth opportunities for ViroPharma and its shareholders.

Contact

Clayton Fletcher
Vice President, Business Development
(610) 321-6789
clayton.fletcher@viropharma.com